Literature DB >> 2788031

Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells.

K K Matthay1, A M Abai, S Cobb, K Hong, D Papahadjopoulos, R M Straubinger.   

Abstract

The rate of uptake and intracellular processing of ligand-directed drug carriers may depend heavily on the endocytic pathway of the target antigen. We examined the role of the target antigen and type of antibody-liposome linkage in determining endocytosis of liposomes by three human T-cell leukemias, Jurkat, CEM, and Molt-4. Liposome-cell binding and internalization over time were studied using two independent assays for intracellular delivery of liposome contents: a new fluorescence assay using a pH-sensitive fluorescent dye; and a growth inhibition assay for delivery of cytotoxic drug, methotrexate-gamma-aspartate. Liposomes targeted against the transferrin receptor showed greater surface binding, internalization, and growth inhibition than liposomes targeted against the T-cell surface antigens, CD2, CD3, or CD5. Furthermore, liposomes made by conjugating the targeting antibody directly to the liposome surface were more efficiently internalized and retained than were liposomes linked to antibody-coated cells via Protein A. Selection of the type of antibody-liposome conjugate as well as the appropriate surface receptor to facilitate endocytosis is essential in antibody-directed drug treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2788031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  DNA/polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression.

Authors:  M Ogris; P Steinlein; S Carotta; S Brunner; E Wagner
Journal:  AAPS PharmSci       Date:  2001

2.  Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture.

Authors:  C J Chu; J Dijkstra; M Z Lai; K Hong; F C Szoka
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

3.  Development of anti-p185HER2 immunoliposomes for cancer therapy.

Authors:  J W Park; K Hong; P Carter; H Asgari; L Y Guo; G A Keller; C Wirth; R Shalaby; C Kotts; W I Wood
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 4.  Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.

Authors:  Xue-Qing Zhang; Xiaoyang Xu; Nicolas Bertrand; Eric Pridgen; Archana Swami; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

Review 5.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor.

Authors:  S Suzuki; K Inoue; A Hongoh; Y Hashimoto; Y Yamazoe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.

Authors:  Sihem Ait-Oudhia; Donald E Mager; Robert M Straubinger
Journal:  Pharmaceutics       Date:  2014-03-18       Impact factor: 6.321

8.  Targeted delivery of CRISPR-Cas9 ribonucleoprotein into arthropod ovaries for heritable germline gene editing.

Authors:  Duverney Chaverra-Rodriguez; Vanessa M Macias; Grant L Hughes; Sujit Pujhari; Yasutsugu Suzuki; David R Peterson; Donghun Kim; Sage McKeand; Jason L Rasgon
Journal:  Nat Commun       Date:  2018-08-01       Impact factor: 14.919

9.  Enhanced antitumor activity and reduced toxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea administered in lipid microspheres to tumor-bearing mice.

Authors:  M Takenaga; R Igarashi; H Tsuji; Y Mizushima
Journal:  Jpn J Cancer Res       Date:  1993-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.